Filing Flows

Filing Flows › 8-K events › Inovio Pharmaceuticals

Inovio Pharmaceuticals: entry into a material definitive agreement

Form 8-K filed Nov 9, 2026 · items 1.01, 7.01, 8.01

Share offeringsINOVIO Announces Proposed Public Offering of its Common Stock

What the filing says

On November 5, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by

Read the filing on SEC EDGAR →

What usually followsAcross 23,535 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 8.01: +0.1% next session across 44,918. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Inovio Pharmaceuticals at a glance

Latest quarterQ1 2025
Revenue$65K
Operating marginn/m
IndustryPharmaceutical Preparations

Inovio Pharmaceuticals, Q1 2025: revenue $65K. The chart follows the revenue to costs, profit and cash.

Inovio Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Inovio Pharmaceuticals’s other material 8-Ks

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.